• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期开始抗痴呆药物治疗可延缓阿尔茨海默病患者进入 24 小时护理:一项芬兰全国队列研究。

Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.

机构信息

Department of Industrial Engineering and Management, School of Science, Aalto University, Espoo, Finland.

MedEngine Oy, Helsinki, Finland.

出版信息

J Alzheimers Dis. 2021;81(3):1103-1115. doi: 10.3233/JAD-201502.

DOI:10.3233/JAD-201502
PMID:33843673
Abstract

BACKGROUND

Dementia is one of the strongest predictors of admission to a 24-hour care facility among older people, and 24-hour care is the major cost of Alzheimer's disease (AD).

OBJECTIVE

The aim of this study was to evaluate the association of early start of anti-dementia medication and other predisposing factors with 2-year risk of transition to 24-hour care in the nationwide cohort of Finnish AD patients.

METHODS

This was a retrospective, non-interventional study based on individual-level data from Finnish national health and social care registers. The incident cohort included 7,454 AD patients (ICD-10, G30) comprised of two subgroups: those living unassisted at home (n = 5,002), and those receiving professional home care (n = 2,452). The primary outcome was admission to a 24-hour care facility. Exploratory variables were early versus late anti-dementia medication start, sociodemographic variables, care intensity level, and comorbidities.

RESULTS

Early anti-dementia medication reduced the risk of admission to 24-hour care both in patients living unassisted at home, with a hazard ratio (HR) of 0.58 (p < 0.001), and those receiving professional home care (HR, 0.84; p = 0.039). Being unmarried (HR, 1.69; p < 0.001), having an informal caregiver (HR, 1.69; p = 0.003), or having a diagnosis of additional neurological disorder (HR, 1.68; p = 0.006) or hip fracture (HR, 1.61; p = 0.004) were associated with higher risk of admission to 24-hour care in patients living unassisted at home.

CONCLUSION

To support living at home, early start of anti-dementia medication should be a high priority in newly diagnosed AD patients.

摘要

背景

痴呆症是老年人入住 24 小时护理机构的最强预测因素之一,而 24 小时护理是阿尔茨海默病(AD)的主要费用。

目的

本研究旨在评估早期开始抗痴呆药物治疗和其他诱发因素与芬兰全国 AD 患者队列中 2 年过渡到 24 小时护理的风险之间的关联。

方法

这是一项基于芬兰国家卫生和社会护理登记处个体水平数据的回顾性、非干预性研究。该病例队列包括 7454 名 AD 患者(ICD-10,G30),分为两个亚组:在家中无需帮助生活的患者(n=5002)和接受专业家庭护理的患者(n=2452)。主要结局是入住 24 小时护理机构。探索性变量为早期与晚期开始抗痴呆药物治疗、社会人口统计学变量、护理强度水平和合并症。

结果

早期抗痴呆药物治疗降低了在家中无需帮助生活的患者(风险比 [HR],0.58;p<0.001)和接受专业家庭护理的患者(HR,0.84;p=0.039)入住 24 小时护理机构的风险。未婚(HR,1.69;p<0.001)、有非正式照顾者(HR,1.69;p=0.003)、或有其他神经障碍诊断(HR,1.68;p=0.006)或髋部骨折(HR,1.61;p=0.004)的患者入住 24 小时护理机构的风险更高。

结论

为了支持在家生活,在新诊断的 AD 患者中,早期开始抗痴呆药物治疗应是重中之重。

相似文献

1
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.早期开始抗痴呆药物治疗可延缓阿尔茨海默病患者进入 24 小时护理:一项芬兰全国队列研究。
J Alzheimers Dis. 2021;81(3):1103-1115. doi: 10.3233/JAD-201502.
2
Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer's Disease.抗痴呆药物对阿尔茨海默病患者死亡风险及死因的影响。
J Alzheimers Dis. 2019;71(4):1297-1308. doi: 10.3233/JAD-190288.
3
[Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].[对接受多奈哌齐、卡巴拉汀、加兰他敏和美金刚治疗的西班牙阿尔茨海默病患者抗痴呆药物持续治疗模式的回顾性比较分析]
Rev Neurol. 2006;43(8):449-53.
4
Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study.抗痴呆药物的早期使用与阿尔茨海默病患者较低的健康和社会护理成本相关:一项芬兰全国性登记研究
Eur J Health Econ. 2023 Dec;24(9):1421-1428. doi: 10.1007/s10198-022-01553-8. Epub 2022 Nov 30.
5
Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.芬兰社区居住的阿尔茨海默病患者使用抗痴呆药物的情况:一项基于全国登记的研究。
Int Clin Psychopharmacol. 2014 Jul;29(4):216-23. doi: 10.1097/YIC.0000000000000032.
6
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.治疗阿尔茨海默病和相关痴呆症的药物治疗:利用与差异。
J Alzheimers Dis. 2020;76(2):579-589. doi: 10.3233/JAD-200133.
7
A population-based study of dosing and persistence with anti-dementia medications.基于人群的抗痴呆药物剂量和持续使用研究。
Eur J Clin Pharmacol. 2013 Jul;69(7):1467-75. doi: 10.1007/s00228-013-1483-y. Epub 2013 Feb 27.
8
Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.抗痴呆药物的使用与阿尔茨海默病老年人患肺炎的风险
Ann Med. 2017 May;49(3):230-239. doi: 10.1080/07853890.2016.1254349. Epub 2016 Nov 29.
9
Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.使用 OMOP CDM 分析新诊断为阿尔茨海默病痴呆症的抗痴呆症药物治疗模式。
Sci Rep. 2022 Mar 15;12(1):4451. doi: 10.1038/s41598-022-08595-1.
10
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?阿尔茨海默病治疗的当前实践:III期试验后证据何在?
Clin Ther. 2015 Aug;37(8):1604-16. doi: 10.1016/j.clinthera.2015.05.510. Epub 2015 Jun 27.

引用本文的文献

1
Relationship between antidementia medication and fracture prevention in patients with Alzheimer's dementia using a nationwide health insurance claims database.利用全国健康保险索赔数据库研究阿尔茨海默病患者使用抗痴呆药物与预防骨折的关系。
Sci Rep. 2023 Apr 27;13(1):6893. doi: 10.1038/s41598-023-34173-0.
2
Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study.抗痴呆药物的早期使用与阿尔茨海默病患者较低的健康和社会护理成本相关:一项芬兰全国性登记研究
Eur J Health Econ. 2023 Dec;24(9):1421-1428. doi: 10.1007/s10198-022-01553-8. Epub 2022 Nov 30.